HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment

por Groheux, D, Giacchetti, S, Hatt, M, Marty, M, Vercellino, L, de Roquancourt, A, Cuvier, C, Coussy, F, Espié, M, Hindié, E
Publicado 2013

Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen

por Giacchetti, S, Porcher, R, Lehmann-Che, J, Hamy, A-S, de Roquancourt, A, Cuvier, C, Cottu, P-H, Bertheau, P, Albiter, M, Bouhidel, F, Coussy, F, Extra, J-M, Marty, M, de Thé, H, Espié, M
Publicado 2014

Clinical value of R-spondins in triple-negative and metaplastic breast cancers

por Coussy, F, Lallemand, F, Vacher, S, Schnitzler, A, Chemlali, W, Caly, M, Nicolas, A, Richon, S, Meseure, D, El Botty, R, De-Plater, L, Fuhrmann, L, Dubois, T, Roman-Roman, S, Dangles-Marie, V, Marangoni, E, Bièche, I
Publicado 2017

Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers

por Coussy, F., El Botty, R., Lavigne, M., Gu, C., Fuhrmann, L., Briaux, A., de Koning, L., Dahmani, A., Montaudon, E., Morisset, L., Huguet, L., Sourd, L., Painsec, P., Chateau-Joubert, S., Larcher, T., Vacher, S., Melaabi, S., Salomon, A. Vincent, Marangoni, E., Bieche, I.
Publicado 2020